The Chinese HCT survey: a non-manipulated haploidentical transplantation procedure makes a novel contribution to data sharing within the regional and global transplant registries and to worldwide knowledge

Dietger Niederwieser 1,2,3

Received: 7 November 2020 / Revised: 23 December 2020 / Accepted: 11 January 2021 / Published online: 29 January 2021
© The Author(s) 2021. This article is published with open access

The article by Xu et al. [1] reports on 12,323 hematopoietic cell transplantations (HCT) by the Chinese Blood and Marrow Transplantation Registry Group (CBMTRG) in a single year (2019) contributing to a total of 58,914 HCT since 2008. Distinguishing features are the predominance of allogeneic (78%) over autologous HCT, the high frequency of haploidentical HCT (60%), the frequent use of bone marrow in combination with peripheral blood stem cells, and an increase in activity of 29% over the previous year. This is a unique experience worldwide.

The activity described by the CBMTRG is timely, impressive, and praiseworthy. After the first publication describing 21,884 HCT from 76 centers over 8 years (2008–2016) [2], the total numbers of HCT have doubled in just 3 years, and the reporting transplant centers increased threefold. The Chinese activity with 12,323 HCT annually is now comparable to that of the entire Asian Pacific region (SEAR/WPR) in 2015 without China (13,032 HCT) [3]. Within the global survey of the Worldwide Network for Blood and Marrow Transplantation (WBMT), China is approaching in 2016 the number of teams in North America (n = 215) and the median HCT/team (82.7 in China versus 93.7 in North America). Considering its population size (1.440 million), China has achieved a remarkable transplant rate (TR; HCT/10 million population) of 86 (Fig. 1) in comparison to 54 in the whole SEAR/WPR and a Team Density (TD; teams/10 million population) of 1.03 [4]. Most importantly, the registry collects the activity every 6 months and is compatible with the Asian Pacific Blood and Marrow Transplantation (APBMT) registry, which contributes to the worldwide survey of the WBMT.

Why is it important to maintain an accurate national, international, and global activity survey?

The whole art of medicine is supported by four important doctrines: observe, record, tabulate, and communicate [Sir William Osler (1849–1919)]. By observing, recording, and finally communicating medical experience we increase the knowledge in the medical field in general and particularly in this highly specialized treatment. HCT is the only curative treatment available for many diseases and is considered a routine although complex procedure. Driven by the necessity to adapt to local resources and availability of donors, a constant evolution is in progress in the different world regions. This local specialization threatens to diminish treatment and technology diffusion worldwide. It is therefore of crucial importance to share information on indications, on specific technologies and trends in HCT to prepare the necessary infrastructure and to avoid errors in planning. To ensure equity, quality and financial risk protection, the guiding principles of the World Health Organization (WHO; www.who.org) declare the transplantation of organs, cells, and tissue to be a global task. The collection of activity is certainly one of the prime prerequisites to identify differences between countries of dissimilar background and income and to support diffusion.

Scientific societies have an essential role to play in exchanging and collecting information on HCT. The need for scientific societies led in the 1970s to the foundation of the Center for International Blood & Marrow Transplant Research (CIBMTR) in North America and the European Society for
Blood and Marrow Transplantation (EBMT) in Europe. APBMT for the Asia Pacific region, the World Marrow Donor Association (WMDA) and the East Mediterranean Blood and Marrow Transplantation (EMBMT) followed. Finally, with the intention of promoting HCT globally, four scientific societies (CIBMTR, EBMT, APBMT, and WMDA) founded the umbrella organization WBMT in 2006 (www.wbmt.org). The WBMT now comprises more than 20 societies working on different aspects of HCT. As a nongovernmental organization in working relation with the WHO from the beginning, the WBMT has taken up the challenge of collecting and disseminating worldwide HCT.

The main tools available to the WBMT are the analysis of activities and trends worldwide, the creation of regional scientific societies, and in cooperation with WHO and local health authorities, the organization of workshops in different world regions. After the foundation of the Latin American Blood and Marrow Transplantation Group (LABMT) and the African Blood and Marrow Transplantation Group (AFBMT) an extensive, worldwide network was established. Starting in 2006, the WBMT undertook biannual publications of the frequencies of HCT worldwide through regional societies or, in location without a regional registry, directly from transplant centers [5–9]. Although overall coverage was high, gaps remained in extremely large countries like China. With the published Chinese activity, a big gap has been largely closed.

The organization of workshops in countries with low activity was an important tool to reach global reporting and increased diffusion using education, twinning, and telemedicine. The main target was to share the accumulated experience covering a range of past errors and successes, but taking into account the regional needs. The final aim was to improve access for all patients in need and to establish a global model for the application of medical products of human origin. Successful meetings cosponsored by the WHO were hosted in Vietnam, Brazil, South Africa and Saudi Arabia. The read out for such meetings were subsequent increases in activities and reporting. One of the workshops was held 2018 in Beijing (China) with the special intent to merge the different registries in the country. The article published in this issue is one of the fruits of this workshop.

What data are collected in HCT registries?

According to their scope, we distinguish between surveys and outcome registries. Surveys are activity registries looking at...
HCT numbers in individual centers documenting donor type, donor matching, stem cell source, disease type, and stage. Since 1957, 1.5 million procedures have been reported worldwide and more than 82,000 HCT collected in 2016 from >1600 transplant centers [4]. Such registry data are important for physicians, health authorities, WHO and WHO member States to detect indications, trends, to provide transparency, avoid inequalities, and learn from each other’s. The annual European surveys are important examples [10].

Outcome registries are collecting instead patient-specific information usually by data managers who collates minimal essential longitudinal outcome data (MED A; TED) and detailed patient, donor, disease and method specific information (e.g., MED B). Outcome registries need adequate databases and quality controls. It is not surprising that outcome registries are usually missing in countries with restricted resources. Here, the WBMT is helping to establish outcome registries, as these will be an essential part of the transplant procedure for quality checking, for listing side effects and complications. Analysis of such outcome registries have influenced daily praxis work such as timing of HCT in CML [11] and selection of unrelated donors [12].

Having now established the national survey, the Chinese Registry is narrowing an essential gap in the completeness of global information. Because of its size (14.9% of worldwide HCT) the provided information will significantly increase the power of the global survey and boost the information on HCT in the Asia Pacific Area. The unique information on haploidential HCT and multiple stem cell sources included in the Chinese registry reports a new successful method for treating patients without a matched donor that adds to the in vitro T-cell depletion and the post-cyclophosphamide techniques. Overall, the Chinese registry is a perfect model of national and international collaboration, exchange, and humanity. The outcome registry is the next step to target.

Acknowledgements The author thanks Helen Baldomero and Michael Cross for helping in the development of the paper. Information of Figure 1 was provided by EBMT, CIBMTR, APBMT, AFBMT, Canadian Blood and Marrow Transplant Group (CTTC) and EMBMT.

Funding Open Access funding enabled and organized by Projekt DEAL.

Compliance with ethical standards

Conflict of interest The author declares no conflict of interest.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Xu L-P, Lu P-H, Wu D-P, Sun Z-M, Liu Q-F, Han M-Z, et al. Hematopoietic stem cell transplantation activity in China 2019: a report from the Chinese Blood and Marrow Transplantation Registry Group. Bone Marrow Transplant. 2020. In press.
2. Xu L-P, Wu D-P, Han M-Z, Huang H, Liu Q-F, Liu D-H, et al. A review of hematopoietic cell transplantation in China: data and trends during 2008–2016. Bone Marrow Transplant. 2017;52:1512–8.
3. Iida M, Kodera Y, Dodds A, Ho AYL, Nivison-Smith I, Akter MR, et al. Advances in hematopoietic stem cell transplantation in the Asia-Pacific region: the second report from APBMT 2005–2015. Bone Marrow Transplant. 2019;54:1973–86.
4. Niederwieser DW, Baldomero H, Atsuta Y, Aljurf M, Seber A, Koh MBC, et al. One and half million hematopoietic stem cell transplants (HSCT): analysis of dissemination and trends up to 2016 from the worldwide network for blood and marrow transplantation (WBMT). 2020. (submitted).
5. Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A, et al. Hematopoietic stem cell transplantation: a global perspective. JAMA. 2010;303:1617–24.
6. Gratwohl A, Baldomero H, Gratwohl M, Bouzas LF, Horowitz M, et al. Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a Global Observational Study. Haematologica. 2013;98:1282–90.
7. Gratwohl A, Pasquini MC, Aljurf M, Atsuta Y, Baldomero H, Foeken L, et al. One million haemopoietic stem cell transplants: a retrospective observational study. Lancet Haematol. 2015;2:e91–100.
8. Niederwieser D, Baldomero H, Szer J, Gratwohl M, Aljurf M, Atsuta Y, et al. Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey. Bone Marrow Transplant. 2016;51:778–85.
9. Baldomero H, Aljurf M, Zaidi SZA, Hashmi SK, Ghavamzadeh A, Elhaddad A, et al. Narrowing the gap for hematopoietic stem cell transplantation in the East-Mediterranean/African region: comparison with global HSCT indications and trends. Bone Marrow Transplant. 2019;54:402–17.
10. Passweg JR, Baldomero H, Basak GW, Chabannon C, Corbacioglu S, Duarte R, et al. The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies. Bone Marrow Transplant. 2019;54:1575–85.
11. Gratwohl A, Hermans J, Goldman J, Arcese W, Carreras E, Devergie A, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Lancet. 1998;352:1087–92.
12. Kollman C, Howe RB, Anasetti C, Antin JH, Davies SM, Filipovich AH, et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood. 2003;98:2043–51.